Evidence map›Paper›PMID 36229840›Full record

ArticleDiagnostic pathology2022

Uterine choriocarcinoma arising from serous carcinoma in a postmenopausal woman: an analysis of next-generation sequencing and PD-L1 immunochemistry.

Meiping Li, Lei Bao, Bo Lu, Wenshun Ge, Lifang Ren

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Meiping LiDepartment of Surgical Pathology, Shaoxing Maternity and Child Health Care Hospital, East Street 305#, Shaoxing, Zhejiang Province, 312000, China. meipingl@126.com.
Lei BaoDepartment of Surgical Pathology, Shaoxing Maternity and Child Health Care Hospital, East Street 305#, Shaoxing, Zhejiang Province, 312000, China.
Bo LuDepartment of Surgical Pathology, Shaoxing Maternity and Child Health Care Hospital, East Street 305#, Shaoxing, Zhejiang Province, 312000, China.
Wenshun GeDepartment of Surgical Pathology, Shaoxing Maternity and Child Health Care Hospital, East Street 305#, Shaoxing, Zhejiang Province, 312000, China.
Lifang RenDepartment of Surgical Pathology, Shaoxing Maternity and Child Health Care Hospital, East Street 305#, Shaoxing, Zhejiang Province, 312000, China.
Shaoxing City Women and Children Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUterine somatic choriocarcinoma is a rare, clinically aggressive malignant tumor. They frequently concur with other cancer. However, the molecular pathogenesis between somatic choriocarcinoma and the concurrent carcinoma has rarely been addressed to date. CASE PRESENTATION: We report a 68-years old Chinese woman with a uterine choriocarcinoma arising from serous carcinoma. The patient underwent radical surgery including total abdominal hysterectomy with bilateral salpingo-oophorectomy, omentectomy and pelvic lymph node resection. She received 10 courses of post-operative chemotherapy. She died of disease 13 months after her surgery. Microscopically, the tumor showed a biphasic pattern of choriocarcinoma and serous carcinoma. The choriocarcinomatous component showed a combination of cytotrophoblast, intermediate trophoblast and syncytiotrophoblast with hemorrhage and necrosis. The component of serous carcinoma was characterized by solid sheets of small cells with marked nuclear atypia and occasional glandular and papillary formation. PD-L1 was exclusively expressed in the choriocarcinomatous component. Next-generation sequencing revealed that the genetic abnormalities were overlapping between the two components.

Indexed as

CarcinomaChoriocarcinomaCystadenocarcinoma, SerousAgedB7-H1 AntigenFemaleHigh-Throughput Nucleotide SequencingHumansImmunochemistryPostmenopauseB7-H1 AntigenChoriocarcinomaEndometriumNext-generation sequencingPD-L1Serous carcinoma

Identifiers

PMID36229840
PMCPMC9563127
OpenAlexW4304957670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.